Vital patent for AlzeCure Alzheimer’s drug
ACD856 is the leading candidate therapy on the company’s NeuroRestore platform
Read More
Tag: AlzeCure
AlzeCure reveals positive NeuroRestore ACD856 data
Therapy is a positive modulator and has demonstrated that it can improve learning and memory
Read More
AlzeCure’s neuropathic pain candidate study reaches crucial phase
Research concerns ACD440 – a non-opioid drug which treats peripheral neuropathic pain
Read More
AlzeCure begins Alzheimer’s therapy development phase
Candidate will go through the development programme, which includes safety and tolerability studies
Read More
AlzeCure’s promising Alzheimer’s abstract accepted
ACD856 has also been shown across preclinical studies to improve cognition and memory
Read More
AlzeCure gets new Alzheimer’s abstract accepted
Therapy is based on ACD856’s indicative disease modifying effects against the condition
Read More
AlzeCure demonstrates disease-modifying effects of NeuroRestore ACD856
Data from the study shows that ACD856 has a potential neuroprotective effect in a cellular mode
Read More
AlzeCure releases results from TrkA-NAM data
Company presents new pain data on the anti-inflammatory effects of its TrkA-NAM
Read More
AlzeCure’s ACD856 research shows positive impact on brain
Exploratory central nervous system analysis shows that ACD856 increases activity in brain
Read More
AlzeCure’s Alzheimer’s candidate shows promise
Treatment abstract focuses on results from a multiple ascending dose study in healthy volunteers
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
